CA2835343A1 - Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories - Google Patents

Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories Download PDF

Info

Publication number
CA2835343A1
CA2835343A1 CA2835343A CA2835343A CA2835343A1 CA 2835343 A1 CA2835343 A1 CA 2835343A1 CA 2835343 A CA2835343 A CA 2835343A CA 2835343 A CA2835343 A CA 2835343A CA 2835343 A1 CA2835343 A1 CA 2835343A1
Authority
CA
Canada
Prior art keywords
pvp
composition
ophthalmic composition
steroid
iodine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835343A
Other languages
English (en)
French (fr)
Inventor
Jason Stein
Michael Weiser
Bo Liang
C. Michael Samson
Joseph CAPRIOTTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47139697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2835343(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of CA2835343A1 publication Critical patent/CA2835343A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2835343A 2011-05-12 2012-05-11 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories Abandoned CA2835343A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485475P 2011-05-12 2011-05-12
US61/485,475 2011-05-12
PCT/US2012/037563 WO2012155062A1 (en) 2011-05-12 2012-05-11 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories

Publications (1)

Publication Number Publication Date
CA2835343A1 true CA2835343A1 (en) 2012-11-15

Family

ID=47139697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835343A Abandoned CA2835343A1 (en) 2011-05-12 2012-05-11 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories

Country Status (16)

Country Link
US (1) US20150038473A1 (enExample)
EP (1) EP2707006B1 (enExample)
JP (2) JP6072009B2 (enExample)
KR (1) KR101967938B1 (enExample)
CN (1) CN103957922A (enExample)
AR (1) AR086399A1 (enExample)
AU (3) AU2012253335B2 (enExample)
BR (1) BR112013028735A2 (enExample)
CA (1) CA2835343A1 (enExample)
CL (1) CL2013003016A1 (enExample)
CO (1) CO6821949A2 (enExample)
EC (1) ECSP13013069A (enExample)
MX (1) MX360666B (enExample)
PE (1) PE20141070A1 (enExample)
TW (2) TWI632914B (enExample)
WO (1) WO2012155062A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665195B2 (ja) 1995-05-19 1997-10-22 日本電気移動通信株式会社 Ｍｃａシステムにおける移動局の個別番号表示方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US20150366879A1 (en) * 2013-02-15 2015-12-24 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing antimicrobial metal
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US11052094B2 (en) * 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
HUE057052T2 (hu) 2016-02-18 2022-04-28 Invirsa Inc 5'-adenozin-difoszfát-ribóz (ADPR) gyógyászati alkalmazása
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
EP3452015A4 (en) * 2016-05-05 2019-12-11 Veloce BioPharma LLC COMPOSITIONS AND METHODS FOR TREATING THE INFLAMMATION OR INFECTION OF THE EYE
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
CN113797164B (zh) * 2020-06-17 2023-07-14 成都瑞沐生物医药科技有限公司 一种眼用制剂的载体或辅料及其制备方法和应用
CN112305115B (zh) * 2020-10-29 2022-08-23 诺峰药业(成都)有限公司 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法
KR20220062790A (ko) 2020-11-09 2022-05-17 정춘영 포비돈 아이오딘계 소독액
US20240082188A1 (en) * 2021-01-21 2024-03-14 Taejoon Pharmaceutical Co., Ltd. Ophthalmic composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
AU2009258145A1 (en) * 2008-06-12 2009-12-17 Foresight Biotherapeutics, Inc. Povidone iodine, a novel alternative preservative for ophthalmic compositions
TWI620569B (zh) * 2009-12-15 2018-04-11 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物

Also Published As

Publication number Publication date
CO6821949A2 (es) 2013-12-31
MX360666B (es) 2018-11-13
EP2707006A4 (en) 2014-09-24
JP2017095474A (ja) 2017-06-01
KR101967938B1 (ko) 2019-04-10
AR086399A1 (es) 2013-12-11
ECSP13013069A (es) 2015-03-31
WO2012155062A1 (en) 2012-11-15
KR20140045375A (ko) 2014-04-16
PE20141070A1 (es) 2014-09-14
TWI632914B (zh) 2018-08-21
MX2013012971A (es) 2013-12-12
US20150038473A1 (en) 2015-02-05
TW201311256A (zh) 2013-03-16
TW201811340A (zh) 2018-04-01
EP2707006B1 (en) 2019-07-03
CL2013003016A1 (es) 2014-05-02
TWI717552B (zh) 2021-02-01
AU2012253335B2 (en) 2016-08-04
AU2016222491A1 (en) 2016-09-22
JP6359619B2 (ja) 2018-07-18
EP2707006A1 (en) 2014-03-19
AU2018203492A1 (en) 2018-06-07
BR112013028735A2 (pt) 2017-12-05
AU2012253335A1 (en) 2013-05-02
JP2014516954A (ja) 2014-07-17
CN103957922A (zh) 2014-07-30
JP6072009B2 (ja) 2017-02-01

Similar Documents

Publication Publication Date Title
AU2012253335B2 (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
JP7081850B2 (ja) 眼科用製剤
US10398725B2 (en) Ophthalmic compositions and methods of use
CA2935366A1 (en) Ophthalmic compositions comprising povidone-iodine
US20120077769A1 (en) Topical ophthalmic compositions containing tobramycin and dexamethasone
CN102118973A (zh) 一种眼科组合物中新的防腐剂替代物聚维酮碘
CN115397392A (zh) 眼用药物组合物
US20190160003A1 (en) Compositions and methods for treatment of inflammation or infection of the eye
NZ751841B2 (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
NZ751841A (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
NZ717573B2 (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
NZ717573A (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
HK1195002B (en) Stable povidone-iodine compositions with bromfenac
HK1195002A (en) Stable povidone-iodine compositions with bromfenac
WO2024108095A1 (en) Semifluorinated alkane antibiotic combination compositions for treatment of ocular disorders
Laitinen et al. Rapid elimination of suprachoroidally injected small molecule drugs into the systemic blood circulation
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
AU2016253668B2 (en) Ophthalmic compositions comprising povidone-iodine
US20190060224A1 (en) Novel ophthalmic composition and methods of use
GR1010821B (el) Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης
HK40004465A (en) Compositions and methods for treatment of inflammation or infection of the eye
US20210213045A1 (en) Novel ophthalmic composition and methods of use
HK1130665B (en) Ophthalmic compositions comprising povidone-iodine
AU2013203462A1 (en) Ophthalmic compositions comprising povidone-iodine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170424

FZDE Discontinued

Effective date: 20220802